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ABSTRACT
MicroRNA 26a (miR-26a) reduces cell viability in
several cancers, indicating that miR-26a could be
used as a therapeutic option in patients. We demon-
strate that miR-26a not only inhibits G1-S cell cy-
cle transition and promotes apoptosis, as previ-
ously described, but also regulates multiple cell cy-
cle checkpoints. We show that sustained miR-26a
over-expression in both breast cancer (BC) cell lines
and mouse embryonic fibroblasts (MEFs) induces
oversized cells containing either a single-large nu-
cleus or two nuclei, indicating defects in mitosis
and cytokinesis. Additionally, we demonstrate that
miR-26a induces aneuploidy and centrosome de-
fects and enhances tumorigenesis. Mechanistically,
it acts by targeting G1-S transition genes as well
as genes involved in mitosis and cytokinesis such
as CHFR, LARP1 and YWHAE. Importantly, we show
that only the re-expression of CHFR in miR-26a over-
expressing cells partially rescues normal mitosis and
impairs the tumorigenesis exerted by miR-26a, indi-
cating that CHFR represents an important miR-26a
target in the regulation of such phenotypes. We pro-
pose that miR-26a delivery might not be a viable
therapeutic strategy due to the potential deleterious
oncogenic activity of this miRNA.
INTRODUCTION
Errors in the regulation of DNA synthesis, DNA repair,
cell-cycle checkpoint progression, chromosome segregation
and completion of cytokinesis can lead to genomic insta-
bility which promotes cancer development and progression
(1). When such instability affects the number or structure
of chromosomes it is referred to as chromosomal insta-
bility (CIN) (2). CIN is known to significantly contribute
to aneuploidy, which is a common driver of many cancers
(3). Aneuploidy can be caused by defects in mitotic check-
points, chromosome cohesion and mitotic spindle as well
as merotelic attachment of kinetochores (4). Mitotic check-
points ensure that once all the chromosomes are aligned
on the metaphase plate they are all properly attached to
the kinetochores (5). In addition, this checkpoint induces
symmetrical tension across the chromosomes, permitting
proper formation of a bipolar mitotic spindle, and a correct
separation of the sister chromatids. It is extremely impor-
tant therefore to have a full understanding of the processes
and factors that ensure a smooth and error-free progression
through all of the stages of the cell cycle.
CHFR has been recently described as a novel mi-
totic checkpoint protein playing a crucial role during the
prophase stage of M-phase (6). It has been shown to de-
lay metaphase entry for cells that experience mitotic stress
through preventing chromosome condensation (7) by stop-
ping accumulation of Cyclin B1 in the nucleus (8). CHFR
has been shown to be epigenetically inactivated in a num-
ber of malignancies including oesophageal, lung and breast
cancers (9–11).
MicroRNAs (miRNAs) are small RNAmolecules able to
post-transcriptionally inhibit gene expression (12). Numer-
ous studies have described a role of miRNAs in cancer and
metastatic progression functioning as either tumor suppres-
sors or oncogenes (13).
miR-26a is an abundant ubiquitously expressed miRNA
which has an important role in various cancers such as
breast (14,15), lung (16) and glioma (17). It acts by inhibit-
ing the G1-S cell cycle transition directly by regulating mul-
tiple specific targets such as Chk1, Wee1 (18), EZ2H (19)
and RB1 (20). miR-26a transient transfection also inhibits
anchorage-independent growth and induces cell-cycle arrest
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and apoptosis in breast cancer (BC), targeting oncogenes
such asMTDH and EZH2 (21). These findings suggest that
the over-expression of miR-26a mimic in cancer patients
may block cell proliferation and could be considered as a
therapeutic option.
Recently, an increasing interest has developed around
the therapeutic potential of miRNAs in the cancer clinic
(22–24). However, this approach requires particular cau-
tion given that a single miRNA can affect multiple tran-
scripts (25), indicating that a comprehensive evaluation of
the genes regulated by a specific miRNA in a particular
tissue is warranted to enable a better understanding of
its therapeutic potential, mechanism of action and poten-
tial side effects associated with. As such, we, and others
have demonstrated that miRNAs can modulate cellular re-
sponses through a complex network of positive and nega-
tive feedback loops to confer robustness to regulative pro-
cesses (26–28). This indicates that either over-expression or
down-regulation of singlemiRNAs could confer deleterious
phonotypical aberrations.
Consistent with this hypothesis, we show here that miR-
26a over-expression in cells does not only inhibit G1-S tran-
sition as previously shown, but also mitosis and cytokine-
sis. Furthermore, we show that miR-26a expression also
mediates comparable phenotypes in embryonic mouse fi-
broblasts (MEFs), suggesting that these miR-26a-mediated
regulative mechanisms have relevance to physiological pro-
cesses other than tumorigenesis and are conserved across
species. In aggregate, we demonstrate that sustained over-
expression of miR-26a in BC initially inhibited cell prolifer-
ation, but later promoted defects in chromosome segrega-
tion and mitosis leading to chromosomal instability (CIN)
and increased tumorigenesis. This indicates that the admin-
istration of miR-26a or mimetic to cancer patients could
have significant detrimental consequences.
MATERIALS AND METHODS
Cell culture
Breast cancer cell lines (MCF-7, MDA-MB-231, SK-BR-3,
T-47D, ZR-75-1) and mouse embryonic fibroblasts (MEFs)
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM). Both were supplemented with 10% fecal calf
serum (FCS), 1% penicillin/streptomycin and 2% glu-
tamine. Stable transfected MDA-MB-231 cell clones were
expanded in G-418 (Roche Applied Science, Burgess Hill,
UK).
Plasmid constructions
miR-26a sponge was constructed by annealing, purifying
and cloning oligonucleotides containing six tandem bulged
miRNA binding motifs, into the HindIII and BamHI
sites of the pEGFP-C1 plasmid (Contech, Saint-Germain-
en-Laye, France), as 3′UTR of the EGFP mRNA. The
CHFR, LARP1, YWHAE andMLC1 3′UTRs cloned into
pLightSwitch 3′UTR GoClone vectors were used (Switch
Gear Genomics, Menlo Park, CA, USA). The indicated
mutagenized or deleted miR-26a seed-containing luciferase
reporter vector was created with a QuickChange II or II XL
Site-Directed Mutagenesis Kit (Agilent Technology, Edin-
burgh, UK) according to the manufacturer’s instructions.
All plasmid sequences were verified to be free of mutations
by direct sequencing.
RNA isolation and real time-qPCR assays
Total RNA from cultured cells was extracted using TRI-
zol reagent following the manufacturer instructions (Invit-
rogen). For relative quantification of either mRNA or ma-
ture microRNA levels, RT-qPCRs were performed as pre-
viously described (29).
Illumina RNA-seq and analysis
Two micrograms of total RNA from each sample was used
to produce cDNA libraries from polyA enriched RNA us-
ing the True-seq RNA preparation kit (Illumina) accord-
ing to themanufacturer’s instructions. Paired end sequences
(reads) 100 nt in length were then generated using a HiSeq
2000 instrument (Illumina). Fastq files containing the se-
quenced reads, obtained at the end of the sequencing, were
mapped to the University of California at Santa Cruz
(UCSC) human genome (hg19 assembly) with TopHat ver-
sion 1.4.1 (http://tophat.cbcb.umd.edu), using default set-
tings. The mapped bam files obtained at the end of the runs
were loaded on the Partek Genomic Suite (Partek Incor-
porated, USA) for quantification of Reads Per Kilobase of
transcript per Million mapped reads (RPKM) normalized
values and analysis. RPKMs represent the computed values.
Significant change in gene expression was selected applying
a Chi squared test.
Transfections, reporter assays and cell treatments
For long-term miRNA or siRNA over-expression, cells
were plated in 6-well plates at 30% confluence, and trans-
fected with the miRNA mimics (5 nM) using HiPerfect
Transfection Reagent (Qiagen, Crawley, UK). After 72 h of
transfection, cells were split and re-transfected with addi-
tional miRNAs mimics; this protocol was repeated every 3
days for up to 9 days. For transient (48 h or 72 h) cell trans-
fection, cells were plated in 6-well plates at 50% confluence
and transfected with miRNAmimics (5 nM) andHiPerfect.
For co-expression ofmiRNAprecursormimics andCHFR-
, LARP1- and/orYWHAE-expressing vectors,MCF-7 and
MDA-MB-231 cells were transfected as described above
with miRNA mimics for 9 days, and co-transfection with
gene-expression vectors was performed for the last 3 days
(MDA) or 6 days (MCF-7) of the experiment. Transfection
was done using Lipofectamine 2000 (Life Technologies Ltd,
Paisley, UK).
For 3′UTR reporter assays, cells were co-transfected
with the indicated miRNA precursors and the specific
3′UTR GoClone reporters (Switchgear Genomics Menlo
Park, CA, USA) in 24-well plates and lysed using a pas-
sive lysis buffer (Promega, Southampton, UK). Next, the
lysates were processed with the LightSwitch Assay System
(Switchgear Genomics Menlo Park, CA, USA) according
to manufacturer’s instructions. Luciferase activity detec-
tion was performed using a GLOMAX 96 Microplate lu-
minometer (Promega).
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For nocodazole treatment, cells were treated with noco-
dazole (50 nM) in normal growth medium. After 16 h,
cells were allowed to enter mitosis by replacing nocodazole-
containing growthmediumwith normal growthmedium for
1 h prior to fixation.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde and perme-
alised in 0.2% Triton-X-100 for 30 min. F-Actin was de-
tected with phalloidin-Alexa Fluor® 488 (Invitrogen) and
nuclei were visualized with DAPI (Invitrogen). For visu-
alization of mitotic features visualisation, cells were co-
stained with  -tubulin antibody (1:500, ab11316) and -
tubulin antibody (1:1000, 79026, Sigma-Aldrich) and im-
aged using an EVOS® FL Cell imaging system (Life Tech-
nologies).
Metaphase spread preparations and flow cytometry analysis
To prepare metaphase spreads, cell were treated with col-
cemid (50 ng/ml, GIBCO BRL) for 4 h at 37◦C. Cells
were then collected, washed with phosphate-buffered saline
and incubated with 75 mM KCl at 37◦C for 15 min. Af-
ter fixing in Carnoy’s solution (75% methanol, 25% acetic
acid), cells were dropped in 20 l-aliquots onto micro-
scope slides and stained them with 5% Giemsa solution.
Metaphase spreads were imaged under light microscopy
and chromosome numbers determined. For fluorescence-
activated cell-sorting analysis, cells were collected, fixed in
ice-cold methanol and incubated with RNase (50 g/ml)
and propidium iodide (PI, 100 g/ml). DNA contents were
determined using a FACSCanto II flow citometer (BD Bio-
sciences).
Soft agar clonogenic assays
After transfection, cells were harvested by trypsinisa-
tion, counted with a Scepter™ Handheld automated
cell counter (Millipore) and resuspended in a 0.3%
agarose/growth medium solution (1 × 105 cells/ml).
Two milliliter of cell/agarose mixture was added in each
well of a 6-well plate pre-coated with 0.6% agarose
in duplicate per condition. Cells were incubated un-
der normal growth conditions for 3–4 weeks to allow
anchorage-independent cell growth. Colonies over 75 nm
in diameter were imaged by light microscopy and then
stained with 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Invitrogen, Life Tech-
nologies Ltd, Paisley, UK) in ddH2O after incubation at
normal cell growth conditions overnight. Each well was
then photographed to visualizeMTT-stained colony forma-
tion.
Analysis of miR-26a expression in patient samples
Analysis of miR-26a expression from TCGA and Buffa
Camps Breast GSE22216 was performed using SurvMicro
(30).
Statistical analysis
Data are presented as mean ± standard error of the mean
(S.E.M.) calculated using Graph Prism software. Student’s
t-test and two-way ANOVA test were used for comparison,
with P < 0.05 considered significant.
RESULTS
miR-26a over-expression leads to formation of large, binucle-
ated cells and increased the number of micronuclei
Transient over-expression of miRNA mimics in cancer cell
lines for 24–72 h is a commonly used procedure to as-
sess the effect of specific miRNAs on cancer cell pheno-
types. MCF-7 and MDA-MB-231 express similar levels of
miR-26a (Supplementary Figure S1). Since transient miR-
26a over-expression has been shown to reduce MCF-7 and
MDA-MB-231 cancer cell properties (14), we questioned
whether a sustained miR-26a expression to better mimic
cancer treatment would have a similar effect on cancer cells.
To this end, we maintained the over-expression of miR-26a
for 9 days in both MCF-7 and MDA-MB-231 following
evaluation of cellular morphology. Unexpectedly, continu-
ous over-expression of miR-26a induced formation of large
cells with aberrant size and/or number of nuclei (Figure
1A–C). MCF-7 and MDA-MB-231 cells derived from the
long-termmiR-26a over-expression had either a single large
nucleus or two nuclei compared to negative control (miR-
n.c) expressing cells (Figure 1A–C) indicating that miR-26a
promotes both mitosis and/or cytokinesis defects. In addi-
tion, such miR-26a over-expression significantly increased
the number of micronuclei (Figure 1D) suggesting possi-
ble aberrations in spindle dynamics (31,32).Moreover, phal-
loidin staining demonstrated that miR-26a induced exten-
sive reorganisation of F-actin in cortical microspikes (Fig-
ure 1B) that has been linked to impaired cytokinesis (33)
and which may explain the increased number of binucleated
cells. To further confirm our observations, we extended our
investigation to three breast cancer cell lines. Accordingly,
over-expression of miR-26a in SK-BR-3, T-47D and ZR-
75-1 breast cancer cells yielded increased nuclear size ac-
companied by an increased number of chromosomes (Sup-
plementary Figure S1B) providing a definitive verification
of the observed miR-26a long term expression related phe-
notype in breast cancer cells.
We also performed a timecourse experiment in MCF-7
and MDA-MB-231 cell lines to assess when changes in-
duced by miR-26a can be observed. Looking at the nuclear
size as a hallmark of miR-26a-induced aberrations, we saw
that the effect can be seen as early as day 3 post-transfection
(Supplementary Figure S1C) with a further increase in the
average nuclear size over the following days.
miR-26a over-expression causes aneuploidy in human cancer
cells as well as in MEFs
Next, we investigated a possible effect of miR-26a on aneu-
ploidy in BC cell lines (Figure 2 and Supplementary Figure
S2). PI staining followed by FACS analysis in MCF-7 cells
revealed a threefold increase in aneuploid DNA content in
cells transfected with miR-26a precursor for 9 days (>6n;
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Figure 1. Prolonged miR-26a over-expression leads to formation of large bi/mononucleated cells with an increased number of micronuclei. (A) Phase-
contrast images of MCF-7 (top panel) and MDA-MB-231 (bottom panel) cells upon transfection with miR-26a and miR-n.c. precursors (5 nM) for 9
days. Scale bar: 100 m. Arrows indicate multinucleated cells. (B) From left to right: DAPI staining of DNA, Alexa Fluor 488 phalloidin (1:500) staining
of F-actin and overlay of the two images of MCF-7 (top panel) or MDA-MB-231 cells (bottom panel) transfected with miR-26a and miR-n.c. precursors
(5nM) for 9 days. White arrows indicate aberrant nuclei; red arrows indicate cortical microspikes. Scale bar: 20 m. The graphs show the percentages of
multinucleated cells observed in the two BC cell lines after long term-transfection with the indicated miRNA precursors. 50–100 cells were counted per
condition in three independent experiments. Data are mean ± S.E.M. (C) The average size of the nucleus in cells transfected with indicated precursors for
9 days was calculated using ImageJ software; 100 cells were calculated per condition. (D) The number of micronuclei in miR-26a and miR-n.c. transfected
cells was calculated following DAPI staining and image acquisition using a confocal microscope. >100 cells were analysed per condition. n = 3.
Figure 2A). Similarly, MDA-MB-231 cells expressing miR-
26a for 9 days displayed an increased number of cells with
abnormally high DNA content (>4n; Supplementary Fig-
ure S2A). This observation was further confirmed by data
obtained frommetaphase chromosome spreads prepared to
assess chromosome number more precisely in both cell lines
(Figure 2B and Supplementary Figure S2B). Accordingly,
both cell lines expressingmiR-26a had a significantly higher
proportion of cells containing an abnormally high number
of chromosomes (>80) compared with control (Figure 2B
and Supplementary Figure S2B). In summary, these results
showed a significantly higher proportion of cells with an in-
creased chromosome number in miR-26a over-expressing
cells, with over 10% of those cells having 80 or more chro-
mosomes in both cell lines. Such state of aneuploidy has
been extensively correlated with CIN (2).
Subsequently, we sought to examine whether the ob-
served phenomena mediated by sustained miR-26a over-
expression could also be demonstrated in non-cancerous
primary MEFs, which would imply a more general role for
miR-26a in regulating other cellular processes. Moreover,
we decided to select a murine cell line in order to assess for
any cross-species conservation of miR-26a-mediated phe-
notypic effects. Comparable to human cancer cellular mod-
els, sustained miR-26a over-expression caused a significant
rise in aneuploid MEFs cells as manifested by an increased
proportion of cells with extra chromosomes (>80; Figure
2B).
Over-expression of miR-26a induces centrosome defects
Since chromosome mis-segregation is often linked to cen-
trosome abnormalities, we stained for  -tubulin centrosome
markers to assess mitotic spindle structures and polarity of
MCF-7, MDA-MB-231 andMEFs (Figure 2C and Supple-
mentary Figure S2C). Over-expression of miR-26a had a
significant impact on centrosome number and polarity sta-
tus of all the analysed cells which was reflected in an in-
creased number of multipolar, monopolar as well as de-
fective bipolar cells. We observed different polarity con-
figurations in multipolar spindles with three or four dis-
tinct poles as well as two, proximally located poles in some
cells, plausibly reflecting cellular centrosome clustering ac-
tivity as an attempt to suppress multipolarity (Figure 2C
and Supplementary Figure S2C). In cancer cells, such spin-
dle polarity abnormalities have been described as a major
cause of incorrect attachment of kinetochores leading to
mis-segregation of chromosomes (34).
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Figure 2. MiR-26a affects cellular DNA content and causes mitotic defects in MCF-7 as well as MEF cells. (A) MCF-7 cells transfected with the indicated
miRNA precursors (5 nM) for 9 days were stained with PI for flow cytometry analysis of DNA content. Data are representative of three independent
experiments. (B) Representative metaphase chromosome spreads of MCF-7 and MEF cells transfected for 9 days with the indicated miRNA precursors.
Magnification: 100×. Percentages of metaphase chromosome spreads containing the indicated ranges of chromosome number. Chromosome number of
100 methaphase spreads was determined per conditions. Data are mean of three independent experiments (P = 0.04, Student’s t-test). (C) Cells were
transfected with the indicated miRNA precursors (5 nM) for 9 days, synchronized with nocodazole and then released for 1 h to increase mitotic feature
observation. Co-immunostaining was performed with  - and -tubulin antibodies and chromosomes were stained with DAPI (individual stain is visualized
in reduced, gray scale images). Cells were visualized with EVOS® FL Cell imaging system (Life technologies). Scale bar: 10 m. Arrows show centrosome
amplification. The graph on the right shows percentage of mitotic spindle types (multipolar, normal, defective bipolar and monopolar spindles) observed.
80–100 mitotic cells were counted per condition. Data are mean of three independent experiments ± S.E.M. (*P < 0.01, **P ≤ 0.001, ***P ≤ 0.0001,
Two-way ANOVA test).
miR-26a regulates several genes that modulate different
stages of the cell cycle
Our results showed thatmiR-26a induces formation of over-
sized cells containing very large, or two nuclei (Figure 1).
Moreover, expression of miR-26a mediated aneuploidy and
centrosome defects in both human BC cell lines and pri-
mary MEFs (Figure 2). In order to identify the genes reg-
ulated by miR-26a that might mediate this striking phe-
notype, we performed RNA-seq in MCF-7 cells following
over-expression of miR-26a for 9 days, and in MDA-MB-
231 cells in which we had induced stable knock down of
miR-26a using amiRNA-sponge strategy (29).We used this
approach to identify genes containingmiR-26a seed regions
that were down-regulated in MCF-7 cells but up-regulated
in MDA-MB-231 cells and hence, provide us with a list of
likely miR-26a direct targets (Supplementary Table S1).
Sequencing our samples (MCF-7 cells transfected with
miR-26a, with miR-negative control (miR-n.c.), MDA-
MB-231 cells stably expressing p-EGFP-C1 empty vector
and expressing miR-26a sponge vector) produced 27, 29, 25
and 33 million reads respectively, which were then mapped
to the Hg19 human reference genome. miR-26a expression
in MCF-7 cells affected the level of 7.4% of genes, whereas
in MDA-MB-231 cells stably transfected with the sponge
vector, gene expression changes were observed in 25.6% of
genes (Supplementary Table S1). To enrich for genes that
were directly regulated by miR-26a, we focused on those
transcripts that were down-regulated in MCF-7 cells over-
expressing miR-26a that overlapped with those transcripts
that were up-regulated in MDA-MB-231 cells stably trans-
fected with a miR-26a sponge construct (sp-26a; Supple-
mentary Figure S3A) and only if they hadmiR-26a recogni-
tion sites predicted by TargetScan analysis (Figure 3A; Sup-
plementary Table S2). We considered a cut-off expression
change of 1.2-fold sufficient since miRNAs regulate tran-
scripts by promoting destabilization through deadenylation
(35,36) but mediate a stronger effect on protein translation
(37), higher fold changes would result in omitting many rel-
evant targets. Furthermore, the impact of miRNAs on gene
targets is variable and is usually mild (38,39). To validate
our analysis, we performed a thorough literature search and
used the miRTarBase database (40) to identify experimen-
tally confirmed targets of miR-26a. Eighty-one percent of
previously described miR-26a gene targets were among the
intersections representing those genes down-regulated in
MCF-7 and/or up-regulated in MDA-MB-231, and those
in the TargetScan list (Figure 3A and Supplementary Ta-
ble S2) indicating the reliability of our methods. In terms of
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Figure 3. Threemitosis-related genes are novel miR-26a targets. (A) Venn diagram representing the number of possible miR-26a targets identified as an area
of overlap between transcripts downregulated in MCF cells over-expressing miR-26a, MDA-MB-231 cells with reduced miR-26a level and TargetScan-
predictedmiR-26a target genes. (B) Chart showing the top five significantly enrichedGO terms found withDAVID bioinformatic tool amongst the possible
miR-26a targets identified as described in panel A. (C and D) MiR-26a targets CHFR, LARP1, MCL1 and YWHAE by directly interacting with their
relative 3′UTRs. Relative luciferase activity levels were measured after 24 h from co-transfection of MCF-7 cells with the indicated 3′UTR-luciferase
reporter constructs either with miR-26a or miR-n.c. precurors (100 nM) or with mi-26a-sponge construct or pEGFP-C1 parental control (150 ng). Panel
D shows luciferase activity levels in cells expressing mutant 3′UTRs which impair miR-26a binding. Data are mean of three independent experiments (each
of them performed in triplicate) ± S.E.M. (*P < 0.05,**P ≤ 0.006,***P ≤ 0.0005). (E) Western blots showing CHFR, LARP1 and YWHAE levels after
transfection for 9 days of the two cell lines with the indicated miRNA precursors (5 nM) and relative densitometric quantifications. -Actin was used as a
loading control. Fold changes in protein expression levels normalised for -actin using ImageJ software are shown underneath each relative protein plot
(*P < 0.01, **P ≤ 0.001, ***P ≤ 0.0001).
genes involved in cell cycle progression, our overlap list con-
tained previously validated targets of miR-26a, including
CCNE2 (41) and RB1 (42). Whilst our analysis identified a
large number of miR-26a genes previously demonstrated to
be involved in G1-S transition, a surprising finding was that
the regulation of cell cycle was not restricted to G1-S tran-
sition but also mitotic cell-cycle was amongst the highest
scoring GO terms among the regulated genes (Figure 3B)
implying a possible undescribed role of this miRNA in the
regulation of mitosis separate to its role in G1-S transition.
miR-26a targets CHFR, LARP1 and YWHAE directly in-
teracting with their 3′ UTRs
Considering the enrichment for miR-26a-regulated cell cy-
cle and mitotic genes among GO terms that we identi-
fied (Figure 3B) and the related phenotypic effects derived
from miR-26a over-expression in cell lines (Figures 1 and
2), we selected three genes with important functions in
mitosis (CHFR, LARP1, YWHAE) (43–45), and cytoki-
nesis (LARP1, YWHAE) (44,46–47) to validate the reg-
ulative interaction of miR-26a with the complementary
seed region located in the three prime untranslated regions
(3′UTRs) of these transcripts. We firstly used RT-qPCR to
confirm that CHFR, LARP1, YWHAE and the positive
controlMCL1 (14) were regulated bymiR-26a (Supplemen-
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tary Figure S3B). Accordingly, the selected transcripts were
down-regulated bymiR-26a over-expression inMCF-7 cells
and, conversely, up-regulated in MDA-MB-231 cells sta-
bly expressing a sponge vector for miR-26a (sp-26a; Sup-
plementary Figure S3B). Next, we confirmed that the cho-
sen targets were important for mitosis-related phenotypes
in BC cells, by silencing each of them inMCF-7 andMDA-
MB-231 and assessing effects on mitotic apparatus struc-
ture (Supplementary Figures S4 and S5, respectively).
Inspection of the 3′UTRs of CHFR, MCL1 and
YWHAE indicated a single miR-26a binding site for these
transcripts with three binding sites for LARP1 (Supplemen-
tary Figure S3C). Subsequently, we confirmed the direct
regulation of these targets by miR-26a, using 3′UTR lu-
ciferase assays followingmiR-26a over-expression or down-
regulation (Figure 3C). Furthermore, site-directed muta-
genesis for the miR-26a binding sites located along the
3′UTRs of these transcripts indicated that miR-26a regu-
lated these transcripts directly, via interaction with the iden-
tified miR-26a binding sites, except for one of the three
LARP1 sites (Figure 3D). Moreover, LARP1, CHFR and
YWHAE protein levels were significantly reduced upon
miR-26a over-expression in both MCF-7 and MDA-MB-
231 (Figure 3E), and levels of the potential targets were in-
creased in both cell lines expressing the sponge constructs
(Supplementary Figure S3D).
Restoration of CHFR expression in cells over-expressing
miR-26a partially rescues miR-26a-induced mitotic pheno-
types
To validate the impact of the identifiedmitosis-relatedmiR-
26a targets on mitotic spindle formation and polarity me-
diated by miR-26a, we over-expressed each corresponding
coding region for 72 h (MDA-MB-231) or 144 h (MCF-7)
in cells transfected with either miR-26a or miR-n.c. pre-
cursor for 9 days (Figure 4). Next, we performed West-
ern Blotting experiments to verify the expression levels of
CHFR, LARP1 and YWHAE after transfection of the two
cell lines with the indicated miRNA precursors and the in-
dicated plasmid cDNA vectors (Figure 4A and B). miR-26a
reduced endogenous protein levels because of the presence
of intact 3′UTRs in their correspondingmRNA transcripts,
whereas the reintroduction of selected, exogenous targets
rescued the expression of their corresponding proteins as
they bypass the miRNA-regulatory stage, in both MCF-7
and MDA-MB-231 (Figure 4A and B).
Since we had demonstrated that knockdown of each
one of the targets affected chromosome separation during
mitosis (Supplementary Figures S4A and S5A) and pro-
duced an increased proportion of cells with an aberrantly
high number of chromosomes (Supplementary Figures S4B
and S5B), we subsequently looked at the effect that re-
introduction of the targets had on the mitotic spindle in
cells over-expressing miR-26a. The overall trend for MCF-
7 (Figure 4C) and MDA-MB-231 (Figure 4D) was a de-
creased number of cells with multipolar spindles. Interest-
ingly, only CHFR re-expression partially rescued the induc-
tion of multipolarity exerted by miR-26a in both MCF-7
and MDA-MB-231 cells (Figure 4C and D). Surprisingly,
YWHAE re-expression in miR-26a over-expressing MDA-
MB-231, but not in MCF-7 cells, partially rescued the cel-
lular multipolarity induced by miR-26a indicating that this
mechanism may be tissue or cell-type specific.
Long-term miR-26a over-expression enhances the tumori-
genic potential of MCF-7 cells
Having established that miR-26a targets mitotic related
genes leading to disruption of both the mitotic spindle and
chromosome segregation, we decided to investigate the tu-
morigenic potential of MCF-7 cells transfected with this
miRNA. To this end, we performed soft agar clonogenic as-
says to examine the ability of these cells to spontaneously
form colonies (Figure 5A) and provide an index of in-
creased tumorigenesis. We observed a significant increase
in the number of colonies formed by the miR-26a over-
expressing cells (Figure 5B). Furthermore, the average size
of the colonies formed by miR-26a-transfected cells were
over three times greater compared to control samples (Fig-
ure 5B). Based on these observations we concluded that the
continuous over-expression of miR-26a increases tumori-
genicity of MCF-7 cells.
Restoration of CHFR expression in miR-26a-transfected
MCF-7 cells partially rescues clonogenic potential ofMCF-7
cells
Next, we evaluated whether re-establishment of normal lev-
els of CHFR, LARP1 and YWHAE proteins in cells trans-
fected with miR-26a would reduce the clonogenic proper-
ties of MCF-7 cells transfected with miR-26a (Figure 6).
Only CHFR re-expression in miR-26a over-expressing cells
partly rescued tumorigenesis induced by miR-26a indicat-
ing that CHFR represents the crucial miR-26a target for the
modulation of tumorigenic potential.We also observed that
CHFR was the only target whose expression significantly
reduced the miR-26a-induced enlargement of cellular nu-
clei (Supplementary Figure S6), implying its important role
in downstream mediation of miR-26a actions.
miR-26a could be highly expressed in either high or low risk
BC patients
Since we demonstrated that the over-expression of miR-
26a had both oncogenic and tumor suppressor effects such
as inhibition of cell proliferation, activation of mitotic de-
fects and increased tumorigenesis we investigated the levels
of miR-26a in high- and low-risk BC patients. To this end
we examined miR-26a expression in selected BC datasets
analysing a total of 1660 BC samples [Buffa Camps datasets
(GSE22216) 210 samples, TCGA Breast Invasive Carci-
noma (Illumina GA) 322 samples and TCGA Breast Inva-
sive Carcinoma (Illumina HiSeq) 528 samples]. We found
that miR-26a expression was significantly higher in low risk
BC patients compared with high risk BC patients in the 850
samples obtained from both TCGA datasets (Supplemen-
tary Figures S7A and S7B), but was significantly higher in
high risk BC patients compared to low risk BC patients in
the Buffa Camps (GSE22216) BC datasets (Supplementary
Figure S7C) confirming that high or low levels could influ-
ence cancer formation.
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Figure 4. Restoration of specific miR-26a targets expression in miR-26a-transfected cells partially rescues miR-26a-induced mitotic phenotypes. (A and
B) Representative Western blots showing CHFR, LARP1 and YWHAE levels after transfection of the two cell lines with the indicated miRNA precursors
(5 nM) for 9 days and with the indicated plasmid vectors for 72 h. -Actin was used as a loading control; pENTRY was used as an empty plasmid control.
Graphs showing percentage of cells with multipolar mitotic spindles observed in MCF-7 (C) or MDA-MB-231 (D) cells transfected for 9 days with the
indicated precursors (5 nM) and for 72 h (MDA) or 144 h (MCF-7) with the indicated vectors (2 g). 80–100 mitotic cells were counted per condition.
Data are mean of three independent experiments ± S.E.M. (*P < 0.05,**P ≤ 0.01,***P ≤ 0.001, ns: non-significant, Student’s t-test.
DISCUSSION
The activity of miRNAs can be efficiently and specifically
inhibited in vivo using chemically modified, stable comple-
mentary oligonucleotides. Conversely, synthetic molecules
that mimic tumor-suppressor miRNAs could be delivered
to patients in order to restore the expression of a lost
onco-suppressormiRNA.Due to these characteristics it has
been widely proposed that anti-miRNAs or miRNA mim-
ics could be used to therapeutically modulate the activity
of ‘onco’-miRNAs or tumor-suppressor miRNAs, respec-
tively. Nevertheless, because miRNAs act by targeting mul-
tiple transcripts through negative and/or positive feedback
loops to confer robustness of regulative networks (26–28),
we hypothesize that long term over-expression of candidate
tumor suppressor miRNAs could have deleterious effects.
miR-26a is an ubiquitously expressed, abundant miRNA
that has been proposed to have tumor suppressing roles
in various tumors, including breast and liver cancers
(15,21,48). Mechanistically, it induces cell cycle arrest and
apoptosis by modulating both cell cycle-related genes such
as CCND2, CCNE2 (48) and anti-apoptotic genes such
as MCL1 (14). Consistent with this hypothesis, the in vivo
delivery of miR-26a using vectors based on an adeno-
associated virus, repressed liver tumor growth in mouse
models (48). Notably, both miR-26a genes are located in
fragile genomic sites that can be deleted (49) or amplified
(17) in cancer indicating that it could also act as an onco-
genic miRNA.
Based on these observations, we aimed to investigate the
phenotypic effects of the sustained over-expression of miR-
26a in MCF-7 and MDA-MB-231 BC cell lines for which
its transient over-expression has been demonstrated to in-
duce cell cycle arrest and apoptosis (14). Surprisingly, long-
term over-expression of miR-26a in these cells induced ab-
normally large nuclei and/or binucleated cells as well as
increased the presence of micronuclei (Figure 1). In addi-
tion, the cells displayed reorganization of actin filaments
in cortical microspikes which indicate cytokinesis defects
(33). Based on the observed phenotypes we propose that
miR-26a modulates mitosis and cytokinesis in addition to
modulating G1-S cell cycle progression (15,21,48). This in-
dicates that, therapeutically, although miR-26a could halt
the proliferation of a large number of cells, a considerable
portion could developmitotic defects, aneuploidy and chro-
mosomal instability, ultimately leading to tumorigenesis.
Importantly, we also demonstrated miR-26a-induced mi-
totic defects in MEFs, indicating that miR-26a regulated
mitotic phenotypes are not restricted to tumor cells and, in
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Figure 5. Long-term miR-26a over-expression enhances tumorigenic potential of MCF-7 cells. (A) Spontaneous colony formation by MCF-7 cells trans-
fected for 9 days with the indicated miRNA precursors and plated on soft agar substrates in 6-well plates. After 3–4 weeks cells were fixed and stained with
MTT. Number of colonies were quantified by using ImageJ software (bottom graph). (B) Single colonies formed as described in (A) were visualized by
light microscopy before colony staining with MTT and the size was quantified by using ImageJ tool (bottom graph). Magnification: 20×. Triplicates per
conditions were assessed in three independent experiments. Data are mean ± S.E.M. (P < 0.0001, Student’s t-test).
addition, are conserved across species. Moreover, elevated
miR-26a levels increased DNA content of both BC cells
and MEFs, which is reflected in our findings of a signifi-
cantly higher percentage of aneuploid cells compared with
a control population (Figure 2A, B and Supplementary Fig-
ure S1A, B). We also demonstrated that over-expression on
miR-26a in MCF-7 cells, MDA-MD-231 cells and MEFs,
led to a significantly higher proportion of abnormal mitotic
spindles (Figure 2C and Supplementary Figure S2C), a fea-
ture which has been shown to induce a variety of cancers
(50–52).
RNA-seq followed by experimental validations indicated
that miR-26a directly regulates the mitosis related genes
CHFR,LARP1 andYWHAE, in addition to the previously
identified G1-S cell-cycle transition and apoptosis related
genes (Supplementary Table S2 and Figure 3) suggesting
the mechanism through which miR-26a regulates mitosis.
CHFR functions as a mitotic checkpoint protein which re-
sponds to mitotic stress and has a role in promoting chro-
mosomal stability (43). Moreover, low levels of its expres-
sion have been linked to aneuploidy, increased proliferation
rates and more a malignant phenotype in BC (53). On the
other hand knockdown of LARP1 has been shown to in-
terfere with chromosome segregation and cause defects in
cytokinesis (44). Furthermore, YWHEA, is a member of
the 14-3-3 family of phosphor-serine/phospho-threonine-
binding proteins, which has not been well-characterised to
date.However,members of this protein family have been im-
plicated in the regulation of anchorage-independent growth
as well as cytokinesis, with their down-regulation linked to
cytokinetic defects (46,47) and the generation of multinu-
cleated cells (54).
We confirmed that the down-regulation of these novel
miR-26a targets by siRNAs promoted mitotic defects, in-
dicating that their inhibition by miR-26a over-expression
could be implicated in the observed phenotypes. In order
to prove this hypothesis, we over-expressed each of the se-
lected miR-26a targets in cells transfected with this miRNA
and noted that CHFR demonstrated a great role in rescuing
the cells frommiR-26a-induced spindle dysfunction in both
MCF-7 and MDA-MB-231 cellular models (Figure 4) as
well as prevention of nuclear enlargement (Supplementary
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Figure 6. Restoration of CHFR expression in miR-26a-transfected cells partially rescues clonogenic abilities of MCF-7 cells. MCF-7 cells were transfected
with the indicated miRNA precursors (5 nM) for 9 days and with the indicated plasmid vectors for 72 h, and subjected to soft-agar clonogenic assays. After
3–4 weeks, colonies were imaged by light microscopy and counted by using ImageJ software. Data are mean of two independent experiments performed
in duplicate ± S.E.M. (*P < 0.05,**P ≤ 0.01,***P ≤ 0.001, Student’s t-test).
Figure S6). Reintroduction of LARP1 and YWHAE did
not seem to rescue the cells from the miR-26a insult. Con-
versely, over-expression of LAPR1 and YWHAE for such a
prolonged period of time in MCF-7 cells, seemed to have a
negative effect on spindlemorphology (increased number of
aberrant spindles in the absence of pre-miR-26a). In case of
LARP1, its over-expression has previously been shown to
be correlated with poor prognosis in colorectal cancer (55)
whilst over-expression of YWHAE in the context of chro-
mosomal stability and cancer has not been described yet.
Based on our results, we believe that a balanced expression
of both of these proteins is required for their correct func-
tion.
All of the identified miR-26a-induced phenotypic
changes are linked to chromosomal instability, which in
turn is known to increase cellular tumorigenic potential
(56). Accordingly, we demonstrated that long-term over-
expression of miR-26a increased the number and size of
colonies formed by MCF-7 cells (Figure 5), which con-
trasts with the finding that transient over-expression of this
miRNA reduces breast tumor formation (14). Moreover,
having performed the rescue experiment (Figure 6), we
observed that CHFR as well as LAPR1 and YWHAE seem
to have a negative effect on miR-26a-induced clonogenic
potential boost. We believe that the global effect of CHFR
over-expression seen across all our rescue experiments,
including prevention of spindle damage as well as nuclear
size reduction, might be due to its specific role as a mitotic
checkpoint protein. Whereas LAPR1 and YWHAE act via
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a different route to reduce clonogenic potential without
preventing errors in mitotic processes investigated by us.
All of the obtained data suggests that CHFR is an impor-
tant miR-26a target for the mitotic defect and tumorigeneis
effect exerted by the miRNA.
Finally, analysis of miR-26a levels in BC clinical samples
indicated that both low and high expression can be signif-
icantly linked with high risk cancer traits (Supplementary
Figure S7).
We propose that miR-26a, through its regulation of
CHFR, has a role in modulating mitosis and cytokinesis in
breast cancer, in addition to its previously identified role as
a modulator of cell cycle arrest. This indicates that the ther-
apeutic use of miR-26a might not be viable because its ex-
pression in patients could induce aneuploidy and chromo-
somal instability that are hallmarks of cancer development
and progression.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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